Strong core growth and raised guidance contrast with LCD pressure and execution risk around the Novaris integration.
| Quarter | Q1 FY26 |
|---|---|
| Length | 59 minutes |
| EPS | $0.05 |
| Revenue | $117.7M |
What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.
Other quarters: Q2 FY26
All CDNA earnings ยท Back to CDNA overview
Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.